1. Home
  2. ATYR vs RR Comparison

ATYR vs RR Comparison

Compare ATYR & RR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • RR
  • Stock Information
  • Founded
  • ATYR 2005
  • RR 2016
  • Country
  • ATYR United States
  • RR United States
  • Employees
  • ATYR N/A
  • RR N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • RR
  • Sector
  • ATYR Health Care
  • RR
  • Exchange
  • ATYR Nasdaq
  • RR Nasdaq
  • Market Cap
  • ATYR 330.7M
  • RR 337.3M
  • IPO Year
  • ATYR 2015
  • RR 2023
  • Fundamental
  • Price
  • ATYR $4.32
  • RR $2.22
  • Analyst Decision
  • ATYR Strong Buy
  • RR
  • Analyst Count
  • ATYR 6
  • RR 0
  • Target Price
  • ATYR $18.60
  • RR N/A
  • AVG Volume (30 Days)
  • ATYR 1.0M
  • RR 15.4M
  • Earning Date
  • ATYR 03-13-2025
  • RR 02-14-2025
  • Dividend Yield
  • ATYR N/A
  • RR N/A
  • EPS Growth
  • ATYR N/A
  • RR N/A
  • EPS
  • ATYR N/A
  • RR N/A
  • Revenue
  • ATYR $235,000.00
  • RR $4,391,000.00
  • Revenue This Year
  • ATYR N/A
  • RR N/A
  • Revenue Next Year
  • ATYR $1,299.74
  • RR N/A
  • P/E Ratio
  • ATYR N/A
  • RR N/A
  • Revenue Growth
  • ATYR N/A
  • RR N/A
  • 52 Week Low
  • ATYR $1.42
  • RR $0.30
  • 52 Week High
  • ATYR $4.66
  • RR $5.20
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 63.39
  • RR 42.84
  • Support Level
  • ATYR $3.38
  • RR $2.50
  • Resistance Level
  • ATYR $3.81
  • RR $3.12
  • Average True Range (ATR)
  • ATYR 0.27
  • RR 0.33
  • MACD
  • ATYR 0.06
  • RR -0.08
  • Stochastic Oscillator
  • ATYR 74.44
  • RR 8.78

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About RR Richtech Robotics Inc. Class B

Richtech Robotics Inc is a developer of new robotic technologies focused on transforming labor-intensive services in hospitality and other sectors currently experiencing unprecedented labor shortages. The company designs, manufacture and sells robots to restaurants, hotels, senior living centers, casinos, factories, movie theaters and other businesses. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company designs its robots to be friendly, customizable to client environments, and extremely reliable.

Share on Social Networks: